Amgen (NASDAQ:AMGN)‘s stock had its “positive” rating reiterated by equities researchers at Jefferies Group in a research report issued on Monday, American Banking and Market News reports.
Other equities research analysts have also recently issued reports about the stock. Analysts at Piper Jaffray Cos. upgraded shares of Amgen from a “neutral” rating to an “overweight” rating in a research note to investors on Monday. Separately, analysts at TheStreet reiterated a “buy” rating on shares of Amgen in a research note to investors on Wednesday, August 21st. Finally, analysts at Maxim Group upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research note to investors on Tuesday, August 20th. They now have a $130.00 price target on the stock.
Twelve analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $112.05.
Shares of Amgen (NASDAQ:AMGN) opened at 105.60 on Monday. Amgen has a 52-week low of $80.60 and a 52-week high of $114.95. The stock has a 50-day moving average of $106.2 and a 200-day moving average of $100.. The company has a market cap of $79.554 billion and a P/E ratio of 17.80.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, July 30th. The company reported $1.89 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.74 by $0.15. The company had revenue of $4.68 billion for the quarter, compared to the consensus estimate of $4.49 billion. During the same quarter last year, the company posted $1.83 earnings per share. Amgen’s revenue was up 4.5% compared to the same quarter last year. Analysts expect that Amgen will post $7.43 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Friday, September 6th. Stockholders of record on Friday, August 16th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 1.78%. The ex-dividend date of this dividend is Wednesday, August 14th.
Amgen Inc is a global biotechnology pioneer that discovers, develops, manufactures and delivers human therapeutics.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.